Biocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets
21.2.2023 17:11:00 EET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets. The Project combines Biocytogen’s proprietary fully human nanobody mouse, RenNano®, with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human nanobody drugs on a large-scale.
Compared to traditional antibodies, nanobodies have smaller molecular weights and improved tissue penetration ability, which make them effective at infiltrating tumors and crossing blood-brain barriers. Additionally, nanobodies generally have longer CDR3 regions which enables them to recognize hidden epitopes better. Due to their simpler structure, nanobodies are more stable and easier to produce and engineer, making them ideal building blocks for complex modalities such as cell therapy, bispecific antibody and engager, multi-specific antibody, antibody drug-conjugate (ADC), and radionuclide antibody-conjugate (RAC).
After several years of endeavor, Biocytogen successfully engineered the RenNano mouse from its fully human antibody mouse, RenMab™. RenNano mouse possesses full human heavy chain variable regions and can produce heavy-chain-only antibodies (HCAbs). The variable regions of HCAbs, i.e., nanobodies, do not require in vitro humanization to develop drugs. Our research has shown that RenNano mouse can generate robust immune responses after immunizations by different antigens. HCAbs generated from the RenNano mouse have highly diverse CDR3 sequences and can recognize many epitopes with nM-level high affinities. In vitro and in vivo experiments have shown that RenNano-derived antibodies have favorable biological functions.
Based on RenNano’s excellent ability to discover fully human nanobodies, Biocytogen has launched the “Nano 100 Project”. The Project aims to develop fully human therapeutic nanobodies against over 100 targets, including tumor associated antigens (TAAs), GPCRs, immune-checkpoints, cytokines, and factors related to neurological diseases. Biocytogen is actively seeking collaborations with global pharmaceutical and biotech companies to combine its large-scale nanobody development abilities with collaborators’ expertise in nanobody-related therapeutics, such as cell therapies, bispecific and multi-specific antibodies, ADCs and RACs, to develop novel drugs with first-in-class and/or best-in-class potentials.
“We believe that with the ability to rapidly develop fully human nanobodies against selected targets, the ‘Nano 100 Project’ will provide our global partners with more diverse and better nanobody building blocks to accelerate the development of novel drugs,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Meanwhile, it is also an important supplement to Biocytogen’s Project Integrum.”
About RenNano®
Biocytogen's proprietary fully human nanobody generating mouse, RenNano, is one of the most comprehensive fully human antibody platforms in the world. Nanobody sequences generated from RenNano mice have the highest possible diversity and do not require antibody humanization, which saves time and cost and reduces the risk of failure during later stages of drug development. Additionally, compared to natural HCAb-producing species like camelids, mice are easier to breed and immunize, making them suitable for developing HCAbs on a large scale.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal antibody, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005554/en/
Contact information
Biocytogen
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AGC Pharma Chemicals Validates Facilities for CDMO Services via Scientist.com’s VERIF.i ® Program1.7.2026 14:55:00 EEST | Press release
Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform and digital marketplace, and AGC Pharma Chemicals, a leading global Contract Development and Manufacturing Organization (CDMO) for small molecule API and HPAPI, announced today that AGC has successfully completed an onsite assessment of its new Barcelona facility using the VERIF.i® supplier pre-assessment program. The newly expanded Barcelona site strengthens AGC’s position as a global leader in the development and commercialization of complex small molecule Active Pharmaceutical Ingredients (APIs) and highly potent APIs (HPAPIs). Designed for maximum flexibility, safety, and energy efficiency, the facility expands AGC’s end-to-end capabilities from gram-scale to ton-scale production under the highest quality and sustainability standards. “At AGC Pharma Chemicals, we place the highest priority on the integrity of our operational processes and the expertise of our frontline teams,” said Jun Kurihar
Introducing Arbex: a New Global Leader in Tissue and Hygiene1.7.2026 14:37:00 EEST | Press release
Arbex, a new global leader in tissue and hygiene, today commences operations as an independent business and unveils details of its brand, leadership team, and company structure. Announced in June 2025 as a $3.4 billion joint venture between Suzano (NYSE: SUZ), the world’s largest pulp supplier, and Kimberly-Clark Corporation (NASDAQ: KMB), a global leader in consumer goods and personal care, the new business will manufacture, market and distribute consumer and professional products across more than 70 markets on five continents. Arbex has assumed ownership of assets previously run by Kimberly-Clark’s International Family Care & Professional (IFP) business unit, which includes 22 manufacturing sites in 14 countries, and a portfolio of more than 40 regional brands including Andrex®, Hakle®, and Scottex®. The company also holds a long-term license for the use of Kimberly-Clark’s global brands, including Kleenex®, Cottonelle®, Scott®, WypAll®, Viva®, and Kimberly-Clark Professional. Ehab A
Klarna has received a favorable ruling in PriceRunner litigation, awarding damages of $1.97 billion1.7.2026 14:19:00 EEST | Press release
Klarna Group plc (NYSE: KLAR) today announces that the court has ruled in PriceRunner’s favor, awarding $1.97 billion in damages in an antitrust case brought by PriceRunner against Google. The award compensates for lost revenue caused by Google's preferential treatment of its own comparison-shopping service over independent price-comparison services, conduct that also drives up costs for consumers. "When markets work well, everyone benefits. Consumers get higher quality at lower cost, companies stay focused on serving customers rather than defending position, and society is better off for it. This ruling supports a healthier, more competitive market for the way people compare products and services — and that is good for everyone who shops," said Dan Greaves, Head of Communications and Policy, Klarna. Klarna acquired PriceRunner in 2022 to add rich product discovery, price comparisons, and product reviews to the Klarna app, and drive high-intent traffic to retail partners. Klarna has si
Objectway Acquires Swiss Private Banking Technology Business From FNZ to Strengthen Its Pan-European Positioning1.7.2026 14:10:00 EEST | Press release
Objectway, a global wealthtech partner for banking, wealth and asset management firms, today announced the acquisition from FNZ of their Swiss private banking technology business FNZ Switzerland SA (formerly operating as New Access). The business will now be operated under the Objectway Switzerland brand. Objectway welcomes a team of over 160 professionals, bringing their expertise and professionalism honed in developing innovative, award-winning solutions for over 40 private banks. The acquisition is a significant step in Objectway’s growth strategy, reinforcing its commitment to expanding its presence in key international wealth hubs such as Switzerland, Liechtenstein, Luxembourg, Monaco and the Bahamas, where the newly joined business already serves both domestic and international cross-border clients. The agreement further expands Objectway’s scalable core-to-digital capabilities supporting end-to-end private banking operations, while leveraging an international team and operationa
NIQ Completes Acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights Business, Expanding Digital Commerce Intelligence Capabilities1.7.2026 14:00:00 EEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that it has completed the acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights business. The acquired business operates in China under the YiMian (“一面”) brand and is a leading provider of eCommerce, social commerce, and digital shelf solutions. The acquisition expands NIQ’s capabilities across China and Southeast Asia and strengthens its ability to measure and understand consumer behavior across retail, eCommerce, social commerce, and digital environments — advancing NIQ’s mission to deliver The Full View™, the most complete understanding of consumer behavior across online and offline channels. It also enhances NIQ’s data and analytics foundation by expanding access to rich digital commerce signals that support the development of more advanced analytics and AI-powered solutions. By bringing together NIQ’s global intelligence, analytics, and retail measurement capabilities with the ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom